RXST
RxSight
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About RXST
Rxsight, Inc.
A developer of photorefractive keratectomy (PRK) and laser-assisted in situ keratomileusis (LASIK) treatments for vision correction
Healthcare Equipment and Supplies
03/05/1997
07/30/2021
NASDAQ Stock Exchange
498
12-31
Common stock
100 Columbia, Aliso Viejo, California 92656
--
RxSight, Inc., was incorporated in California on March 5, 1997 and re-registered in Delaware on July 6, 2021. The company is a commercial-stage medical technology company focused on improving vision in patients following cataract surgery. The company's proprietary RxSight dimmable lens system, consisting of the company's RxSight dimmable lens, RxSight projection device and accessories, is the first and only commercially available intraocular lens technology that enables physicians to customize and optimize vision for patients after cataract surgery.
Company Financials
EPS
RXST has released its 2024 Q4 earnings. EPS was reported at 0.03, versus the expected -0.01, beating expectations. The chart below visualizes how RXST has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RXST has released its 2024 Q4 earnings report, with revenue of 40.21M, reflecting a YoY change of 40.71%, and net profit of -5.94M, showing a YoY change of 35.29%. The Sankey diagram below clearly presents RXST’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
